Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Raises WUXI BIO (02269.HK) TP to $51 on Profit Alert Beat, Strong Order Momentum
Recommend 4 Positive 8 Negative 3 |
||||
|
||||
|
WUXI BIO (02269.HK)'s pre-announced 2025 results exceeded market consensus and JPMorgan's expectations, JPMorgan published a research report saying. The Company anticipated its full-year revenue to be RMB21.8 billion, up 16.7% YoY, broadly in line with market consensus and the broker's forecast. Net profit is expected to reach RMB4.9 billion, approx. 11%/ 17% higher than market consensus/ JPMorgan's forecast respectively. The broker raised its sales forecasts by 2-5% 2025-2027 and 6-9% for 2028 and beyond, due to better new order gain momentum. JPMorgan now projected 2026/ 2027 sales growth to be 17.3%/ 18.0% each. Therefore, the broker raised its target price from $37 to $51, and extended the target price deadline by six months to December 2026, with rating kept at Overweight. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
